Carmel Capital Partners LLC Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Carmel Capital Partners LLC increased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 50.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,396 shares of the medical research company’s stock after purchasing an additional 3,838 shares during the period. IQVIA accounts for 0.9% of Carmel Capital Partners LLC’s investment portfolio, making the stock its 21st biggest position. Carmel Capital Partners LLC’s holdings in IQVIA were worth $2,239,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Smith Group Asset Management LLC purchased a new stake in IQVIA during the fourth quarter valued at about $1,616,000. Simplify Asset Management Inc. grew its position in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares during the period. Nordea Investment Management AB grew its position in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the period. Hickory Asset Management Inc. purchased a new stake in IQVIA during the fourth quarter valued at about $941,000. Finally, Fifth Third Bancorp grew its position in IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after acquiring an additional 1,521 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. UBS Group decreased their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Monday, February 10th. Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 target price (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Bank of America decreased their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Trading Up 1.3 %

Shares of NYSE IQV opened at $186.04 on Thursday. The stock’s 50 day moving average price is $198.24 and its two-hundred day moving average price is $213.66. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $261.73. The stock has a market capitalization of $32.80 billion, a P/E ratio of 24.81, a PEG ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.